Lots of news from Dexcom recently! Stacey talks with retired Chief Technical Officer Jorge Valdes about the Apple Watch announcement and much more. (This interview took place just before the FDA approved Dexcom G5 for Android, but that news is covered in the episode).
Stacey also talks about the news that Beyond Type 1 is taking over Diabetes Hands Foundation's TuDiabetes.org and EsTuDiabetes.org
Stacey shares her personal connection to DHF and mentions this Big Blue Test video that she and her son made a few years ago.
Jason Gensler has the unique experience of being one of the longest users of one of the newest insulin pumps. He started in a pivotal trial of the Medtronic 670G two years ago and has been allowed to keep using it ever since. Jason shares his misgivings about going back to Medtronic; he had a bad experience with a previous pump and sensor. He also talks about why he feels this system is revolutionary and has given him a new way of looking at managing T1D.
This interview is the first we're sharing that was not conducted by Stacey. Jason is interviewed by Weston Nordren, Vice President of the Nightscout Foundation and Community Outreach for the Foundation. It was originally presented as a video (you can watch here)
Note: Jason Gensler does NOT work for Medtronic and is not compensated by them. He did not pay for the pump/sensor system as he received it as part of a clinical trial.
This week, Ed Damiano talks about his Bionic Pancreas project. Using a pump called the iLet and a Dexcom CGM, the only information the Bionic Pancreas needs is the user's body weight. It adapts to you, no need to figure out insulin to carb ratios or correction factors. The iLet will eventually come to market using both insulin and glucagon, but the first version will be insulin-only.
Stacey & Ed talk about the long journey to get to this point, why he had to start a brand new kind of company (Beta Bionics) to help bring the iLet to market and just when he expects it to be available.
Stacey also shares some of what she learned at the recent HealthEVoices Conference and talks about the milestone of this episode: It's the 100th regularly scheduled show for Diabetes Connections!
Anthony Hightower has used Afrezza for the past two years. He credits it (along with a Toujeo, a newer basal insuin) with completely changing his T1D management. In addition to excellent numbers, Anthony shares what else Afrezza has to offer. He explains, he liked it so much, he went to work for Mannkind, the company that makes Afrezza. He and Stacey also talk about the challenges Anthony faced since his diagnosis as a teenager. He admits he spent 20 years trying to avoid thinking about diabetes and credits the online community & the Diabetes Unconference with saving his life.
Stacey also shares what those little "clips" are that come with some pump insets. Her family learned the hard way at the beach a while back! She shares how her husband McGyver'd a solution when they'd left the clips at home.
And, find out how to contribute to our 100th episode coming up soon!
Tom Brobson is JDRF's National Director of Research Investment Opportunities. He was diagnosed with type 1 as an adult and has been involved personally in many artificial pancreas trials, the first of which had him hooked up to a computer in the hospital and not allowed to get up or go anywhere without a healthcare professional by his side. Of course, since then, the trials have included trials with equipment as small as a pump, CGM & smart phone.
Stacey recorded Tom as he gave a presentation at a local JDRF walk kickoff event. He talks about stem cell research, the artificial pancreas project and other advances in diabetes technology. He also talks about approvals and access.
In this episode, Stacey also talks about coughing for pain relief during shots and insertions. Really! We also share the adventures of people with T1D in the Arctic and in Alaska as this episode is released.
This week: OpenAPS, Looping, Happ - a bunch of weird sounding terms that are changing the way many manage diabetes. Tim Street has lived with type 1 for 28 years, he writes a blog called Diabettech. Tim talks about the DIY systems out there right now (he's tried almost all of them) and about all the new choices for people with diabetes available now an in the next few years. Lots of conversation in this show about the “art of the possible."
It's also Diabetes Podcast Week! This is the second year of Stacey's campaign to bring together podcasters and video bloggers to benefit Spare a Rose, Save a Child. Diabetes in developing countries can be a death sentence. This Valentine’s day, considering donating the cost of just one rose. That can keep a child with type 1 alive for a month. A dozen roses? That cost can cover a year. Spare a Rose benefits Life for a Child, an International Diabetes Federation Program.
This week, a conversation with Dexcom’s Chief Technical officer Jorge Valdes. Stacey talks with him about challenges and advances in 2016 and they look ahead to what's in the works for next year. Valdes shares what the FDA is currently considering and may approve for 2017, updates us on customer service issues and reacts to Medtronic's hybrid loop system coming out in the spring.
This is our last episode of 2016; there will be no new show released next week. Please check out our archives or search for your favorite topics or guests from the home page. And make sure you sign up for our newsletter (click here). If you didn't win our Sugar Linings Swag contest, we've got a coupon code going out before the end of the year.
Happy Holidays and a safe and happy New Year!!
This week, a big step forward for diabetes technology. The FDA recently approved the very first hybrid closed loop insulin system: the Medtronic MiniMed 670G. Medtronic's Chief Patient Officer Louis Dias and Social Media Manager Karrie Hawbaker talk to Stacey about what this product is, what it isn’t, access to it and what comes next.
Our Community Connection this week features a unique fundraiser, The Elbow Bump Challenge. Find out how 9-year-old Logan hopes to help out his favorite conference, Children with Diabetes, Friends For Life.
And Stacey talks about the Joslin Medalist Study for people living with type 1 for more than 25 years.
Important information this week about Glucagon, emergency treatment for severe low blood sugar. Stacey talks to Julie Settles, the US Medical Lead for Glucagon at Lilly. We find out more about how Glucagon works, when to use it (and when not to) and what the company is working on to make the delivery easier.
Community Connection this week is with James Wedding who convinced an academic summer program to change their Glucagon emergency use policy.
Plus, learn about the Big Blue Test from Diabetes Hands Foundation.
The Type Zero Technologies artificial pancreas project is one of the many racing to market. Their technology comes from years of research, still ongoing, at the University of Virginia. This summer, they announced a new partnership with Tandem. Molly McElwee Malloy, who has type 1 herself, is the head of patient engagement for Type Zero. She talks about the studies, the progress and the emotional and mental side of artificial pancreas projects.
Plus, necessity is the mother of invention and diabetes moms are nothing if not resourceful. In our Community Connection, the inventor of Diabetic Dabs talks about how she come up with this idea. Liz Sacco shares the story of how her son's diagnosis led her to find a why to clean up after finger sticks.
This week, Animas sent a letter to patients and talked to news media about a potential security issue. You can read more here.
Stacey speaks to endocrinologist Dr. Brian Levy, the chief medical officer with Animas.
This week, a conversation with some of the top executives at Animas, checking in on their newest products in development, the latest research and their company plans. Stacey talks to John Wilson, the Worldwide Vice President, Insulin Delivery for Johnson & Johnson and Krishna Venugopalan, the Worldwide Director of Research & Development, Insulin Delivery. They talk about Animas’s version of a hybrid closed loop, further Dexcom integration, remote capabilities and much more.
Stacey also gives her take on all the talk around the "Artificial Pancreas" vs "Hybrid Closed Loop" language that came with the announcement that Medtronic received approval for a first of its kind device.
And we mention the Diabetes Dance Dare, a new social media challenge from the American Diabetes Association.
When you deal with diabetes you deal with a lot of numbers and a lot of data. This week's guest is Dexcom's Senior Vice President of Data Annika Jimenez. She joined the company in 2015 with a Silicon Valley background and brings us up to date on Dexcom's Clarity software program, developments to come and Dexcom's relationship with Nightscout and OpenAPS developers.
In our Community Connection segment, Stacey talks to Sarah Harmon, founder of Poppy Medical ID. As a teenager, Sarah hated wearing a clunky medical bracelet, so she created a new line of ID jewelry. Poppy Medical ID is currently featured on Kickstarter.
Stacey also explains that her contest continues. Leave a review and you could win a gift card. Details here - contest ends September 27, 2016
It's one of the challenges of insulin pumps and continuous glucose monitors: how to keep them on in water, hot weather and sweaty situations. This week, advice from the experts and from listeners about what works. Stacey talks to Certified Diabetes Educator Lisa Foster-McNulty, the director of patient care and education for Integrated Diabetes Services. We also hear from listeners who explain what works for them in the pool, during hot yoga(!) and through sweaty sports.
Stacey also gives an update on the start of middle school for her son and how their new communication system is working.
Bigfoot Biomedical came on the scene in 2014 determined to change the way companies look at diabetes technology. They've moved forward quickly and are now starting their first clinical trial for their "Smartloop" automated insulin delivery system. Stacey talks to Bigfoot Chief Engineer Lane Desborough about what this system is, what the trial is testing, and how you can find out if you're eligible to enroll.
Desborough is also the co-creator of Nightscout, the free, open source CGM remote monitoring system and is credited with coining the term "We are not waiting." Like all four founders of Bigfoot, Desborough has a child with type 1 diabetes.
Imagine a social media network where what we say about our lives with diabetes actually drives research. It’s out there, and it’s called Glu. Outreach manager Anna Floreen explains what Glu, and the T1D Exchange are, and how they help researchers focus on what really matters to people living with diabetes and their loved ones. Anna was diagnosed with type 1 at the age of 6. She found great support at camp and recently took part in one of the Bionic Pancreas trials. She tells Stacey how surprised she was at how much of the mental burden of diabetes was lifted, and how difficult it was at the end of the trial to give that up.
Dexcom has released a few new studies about how people use their continuous glucose monotoring systems. Stacey talks about them with Tomas Walker, Dexcom’s Director of Clinical Projects and a certified diabetes educator. The two studies, released at the American Diabetes Association's Scientific Sessions look at how people use a CGM in the real-world, outside of a clinical setting.
For example, the FDA does not currently label Dexcom for use in making insulin dosing decisions; we are supposed to always confirm with a finger-stick. Of course, not everyone does this and Dexcom wanted to learn more about how and why. Another study looks at how setting the threshold alerts (the high and low alerts) within the system affect how people use a CGM and whether their blood sugar outcomes and A1Cs are affected.
In this episode, Stacey also announces the winners of the Pebble Time Smartwatch Giveaway (thanks to all who entered)!
She also talks about carrying supplies when in different theme parks, including going over the rules for carrying bags on rides at Disney World and Universal.
The FreeStyle Libre is a newer way to check blood glucose levels but is not yet available in the United States. The system consists of a sensor, with a wire underneath the skin, like a traditional Continuous Glucose Monitor and a controller. To see blood glucose readings the user holds the controller up to the sensor. Abbott Diabetes Care calls the Libre a Flash Glucose Monitor. Stacey talks to Abbott’s Senior Director of New Product Innovation, Joel Goldsmith. As of this airing, the Libre is available in Europe and is expected to launch in Australia in a few weeks. Stacey also talks about the end of the school year, looking ahead to Middle School for her son with type 1 and advice about 504 plans.
Stacey talks with Dexcom CEO Kevin Sayer to mark the ten year anniversary of the company's first commercial product sale and to discuss improvements to customer service. Sayer talks about the long hold times and other issues customers have noticed recently, and explains why the recent growth of the company, along with a product recall, made those difficulties worse. We find out what Dexcom is doing to improve service and make the overall customer experience better. Sayer also answers questions about Android capability for Share and talks about other improvements coming to the system's receiver and inserter.
Howard Look formed Tidepool after his daughter was diagnosed with type 1 in 2011 and, as a self-described "geek-dad" he was frustrated with the lack of access to her diabetes data. Tidepool is a platform for diabetes information and the apps that use it. It includes an uploader to get information off of devices like CGMs and insulin pumps and view them in a clear and accessible way. Look talks about the other features of Tidepool which help you make sense of what you're seeing. He also shares how his family uses Tidepool to make their diabetes management easier. Tidepool was honored at the White House last year and Howard Look shares his experience of being asked to sit on a panel with President Obama in February. Stacey also talks to a North Carolina father participating in the American Diabetes Association's' Tour de Cure. He got involved because his daughter's best friend has T1D and she wanted her friend to have a sleepover. The family got educated about type 1 and their involvement took off from there.
Dr. Ed Damiano is the developer of the bionic pancreas, a closed-loop system that uses a pump and a CGM to automate delivery of insulin as well as glucagon currently in clinical trials. Dr. Damiano got the idea for a dual-chambered system when his son was diagnosed with type 1 at the very young age of 11 months. Dr. Damiano talks to Stacey about the system, now called the "iLet" and about the new company formed to help bring it to market. Called Beta Bionics, it's a unique kind of company, perhaps the first of its kind in the diabetes sector. Dr. Damiano explains what a public benefit corporation is and why he felt it was necessary to form one in order to get the iLet from prototype to commercial product. In this episode, Stacey also shares the story of her family's first JDRF Walk almost ten years ago and how her daughter, who doesn't have diabetes, reacted to the idea of raising money for better research.
"The Human Trial" is a documentary in process about a potential new treatment for type 1 diabetes. Stacey talks to director Lisa Hepner about her life with type 1 and why she wanted to share this story. The movie features ViaCyte, a California biotech firm testing a stem cell treatment for T1D. They have FDA approval to test only the fourth embryonic stem cell-derived product in the world in people. As those human trials progress, Hepner and her crew are there to film the process. They hope to use the documentary to spread awareness and education about type 1 and about the encapsulation method. In this episode, we learn what ViaCyte is, all about encapsulation and why so many researchers and scientists are excited about these latest trials.
A few years back, Scott Hanselman wrote a post some have called a seminal moment in the diabetes community. Called "The Sad State of Diabetes Technology in 2012," it sparked action, particularly in what's now known as the #WeAreNotWaiting movement. We talk to Scott about what he thinks about diabetes technology today, how he manages his own T1D and why a cross-country airplane trip is a perfect diabetes analogy. Community Connection this week is all about programs for adults with type 1. Camp Nejeda in New Jersey will host a weekend session in May. Information about that "Survive and Thrive Boot Camp," and ideas about how to begin something like that where you live.
(Note: due to some technical issues, "helpful links" for this episode may not appear until 24 hours after the episode goes live. Apologies for the delay)
Stefany Shaheen says she was skeptical when her family decided to try a Diabetes Alert Dog for their daughter, Elle. She shares their story and explains what to ask before deciding whether an alert dog is right for you. Shaheen's book, "Elle & Coach: Diabetes, The Fight for My Daughter's Life and the Dog Who Changed Everything" comes out in paperback this month. Stacey also talks to Dexcom Research and Development Senior Vice President Jake Leach about the new G5 mobile app for the Apple Watch and much more.
In 2013, Bryan Mazlish created a home-made artificial pancreas system for use by his wife and son, both of whom have type 1 diabetes. Because Mazlish preferred to stay anonymous, a reporter dubbed him "Bigfoot." In 2015, Mazlish went public and partnered with two others to create Bigfoot Biomedical. Their goal is to bring this technology & other products to market in order to improve the lives of people with T1D. In our Community Connection, Stacey finds out about Hockey Fights T1D, a new JDRF fundraiser in upstate NY sparked by a two year old's diagnosis.